Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies
Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development
Xenetic Biosciences: Q1 Earnings Snapshot
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies...
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers
Xenetic Biosciences: Q4 Earnings Snapshot
Adjourns 2025 Annual Meeting of Stockholders
FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology...
Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners